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Newly designed pyrrolo[2,1-c][1,4]benzodiazepines tricyclic skeleton has
shown potential clusters of cannabinoid receptors CB1/CB2 selective ligands.
CB2 plays a critical role in microglial-derived neuroinflammation, where it
modulates cell proliferation, migration, and differentiation into M1 or M2
phenotypes. Beginning with computer-based docking studies accounting the
recently discovered X-ray crystal structure of CB2, we designed a series of
PBD analogs as potential ligands of CB2 and tested their binding affinities.
Interestingly, computational studies and theoretical binding affinities of
several selected (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs, have
revealed the presence of potential selectivity in binding attraction toward CB1
and CB2. Reported here is the discovery of the first representatives of this
series of selective binding to CB2. Preliminary data showed that this class of
molecules display potential binding efficacy toward the cannabinoid receptors
tested. Intriguingly, initial cannabinoid binding assay showed a selective
binding affinity of 4g and 4h showed Ki of 0.49 and 4.7 μM toward CB2
receptors while no binding was observed to CB1. The designed leads have
shown remarkable stability pattern at the physiological pH magnifying their
therapeutic values. We hypothesize that the PBD tricyclic structure offers the
molecule an appropriate three-dimensional conformation to fit snugly within
the active site of CB2 receptors, giving them superiority over the reported
CB2 agonists/inverse agonists. Our findings suggested that the attachment of
heterocyclic ring through the condensation of diazepine hydrazone and S- or
N-heterocyclic aldehydes enhances the selectivity of CB2 over CB1 [1].
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2.5 nM [3H]CP-55,940. Total binding was assessed in the
presence of equal concentration of DMSO while non-
speci!c binding was determined in the presence of 10 !M
CP-55,940, and background binding was determined in
wells lacking membrane. Following incubation at 30 °C for
60 min, the binding reactions will be terminated by !ltration
through Whatman GF/C !lters. The !lters will then be
washed twice with ice-cold buffer (50 mM Tris-HCl, 1 mg/
mL BSA). Liquid scintillation cocktail was added to each
well and the total tritiated counts per minute were analyzed
using a TopCount scintillation counter. Background counts
were subtracted from all wells and the percent displacement
from total binding was calculated.
The compounds were initially screened at 10 !M con-
centrations. If they produced at least ±30% displacement of
the radioligand, then full competition curves was con-
structed. Ki values were calculated using GraphPad Prism
(San Diego, CA) and Kd values determined using a 1 site !t.
All assays were run in technical and biological replicates so
that the n= 5–6.
Results and discussion
1. Chemistry
A series of (S,E)-11-[2-(arylmethylene)hydrazono]-PBD
analogs were synthesized via previously reported methods
and new approaches in high yield. The synthesis of all PBD
derivatives began from a readily available basic structure of
PBD natural product from Isatis indigotica. As shown in
(Fig. 2), the cyclocondensation of equimolar mixture of L-
proline nd isat ic anhydride in DMF at 155 °C afforded the
dilactam 1. Crystallization of dilacta 1 has been executed
in 10:1 v/v mixture of acetone and DMF to obtain com-
pound 1 as white crystals. Thionation of compound 1 with
0.5 equiv of 2,4-bis-(4-methoxyphenyl)-1,3-dithia-2,4-
diphosphetane-2,4-disul!de (Lawesson’s reagent) in THF at
room temperature generated thiolactam 2. Then treatment of
2 with hydrazine monohydrate in ethanol at room tem-
perature afforded compound 3 which was further used as
the core precursor for the synthesis of (S,E)-11-[2-(aryl-
methylene)hydrazono]-PBD analogs (4a–4h). The title
compound 3 was subjected to condensation with several
aldehydes in anhydrous MeOH and molecular sieves (3 Å)
at room temperature to give a series of highly conjugated
Schiff base 4 in high yield. Compound 4 h was synthesized
from the sequential condensation of 3 and N-Boc-protected-
indole-3-carboxaldehyde via the Schiff base template con-
densation reaction followed by N-Boc deprotection in the
presence of excess K2CO3. Upon further crystallization of
crude product from EtOAc/hexanes, pure 4a–4h were
formed as crystalline solids.
2. Docking studies
A. Molecular docking with CB1
Herein we explore the plausible binding mode of 4b, 4g and
4h into the orthosteric pocket of CB1 crystal structure
(PDB:5XRA) [25]. This is a high resolution CB1 crystal
structure with a synthetic full agonist AM11542, which
takes an L-shape conformation inside the pocket (Fig. 3).
The interactions between AM11542 and CB1 are mainly
hydrophobic and aromatic; the tricyclic tetra-
hydrocannabinol ring system of AM11542 forms "–"
interactions with Phe268, Phe379, Phe189, Phe170 and
Phe177, and the phenolic hydroxyl at C1 forms a hydrogen
bond with Ser383. Similar to AM11542, 4b adopts an L-
shape conformation in the orthosteric-binding pocket. Its
interactions into CB1 are mainly hydrophobic and aromatic
with residues embedded in the extracellular loop 2 [26, 27].
The tricyclic PBD ring system (the head) of 4b forms "–"
interactions with Phe108, Phe170, Phe179 and Phe379, and
the ethylbenzene (the end-tail) maintain two interactions
with Trp279 and Met363. On the contrary, 4g and 4h failed
to occupy the pocket in the correct shape and did not form
any signi!cant intermolecular interaction with the critical
Fig. 2 Reagents and conditions:
(a) DMF, 155 °C, 5 h, 82.0%;
(b) Lawesson’s reagent, THF, rt,
15 h, 87.0%; (c) N2H4.H2O
(98%), EtOH(abs.), rt, 15 h,
99.0%; (d) Aldehydes, MeOH
(anhy.), rt, 15 h, 95.0%
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Fig. 1 Reagents and conditions: (a) DMF, 155 °C, 
5 h, 82.0%; (b) Lawesson’s reagent, THF, rt, 15 h, 
87.0%; (c) N2H4.H2O (98%), EtOH(abs.), rt, 15 h, 
99.0%; (d) Aldehydes, MeOH (anhy.), rt, 15 h, 
95.0% 
Fig. 2 Binding modes of selected compounds into CB1 orthosteric-binding 
pocket. (a) Native ligand AM11542 (yellow sticks) (b), (c) and (d) 4b, 4g, and 
4h (green sticks), respectively. Key amino acid residues shown as blue sticks; 
non-Carbon atoms are colored by element. Settled intermolecular interactions 
(black dotted lines). Some amino acids were hidden for clarity
Fig. 3 Binding modes of selected compounds into CB2 orthosteric-
binding pocket. (a) Native ligand AM10257 (yellow sticks), (b), (c) and 
(d) 4b, 4g, and 4h (green sticks), respectively. Key amino acid residues 
shown as cyan sticks; non-Carbon atoms are colored by element. Settled 
intermolecular interactions (black dotted lines). Some amino acids were 
hidden for clarity
Fig. 4 Binding affinities of compounds 4a–h toward CB1 and CB2
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